Genome Editing for the treatment of human Disease Network

GenEHumDi recommended activities

Events in June 2024

Monday Tuesday Wednesday Thursday Friday Saturday Sunday

Category: General 10:00 am: YOUNG RESEARCHERS WEBINAR SERIES: "Strategies and tools for ex vivo and in vivo genome editing" by Pof. Marc Güell


May 27, 2024

May 28, 2024
May 29, 2024
May 30, 2024
May 31, 2024
June 1, 2024
June 2, 2024
June 3, 2024
June 4, 2024

Category: General CRS webinar"Joining the dotsConnecting Science and Busines"

June 5, 2024

Category: General Untitled Event

June 5, 2024

June 6, 2024

Category: General 1:00 pm: Monthly Meeting COST CA21113 WG6 - Regulatory, Technological Transfer & Industry


June 7, 2024

June 8, 2024
June 9, 2024
June 10, 2024

Category: General 3:00 pm: YOUNG RESEARCHERS WEBINAR SERIES: "CRISPR Clinical Trials: Current progress and future perspectives in ex vivo approaches" by Pof. Annarita Miccio


June 11, 2024

Category: General 2024 annual general meeting of the EFFAB (European Forum of Farm Animal Breeders)

June 12, 2024 June 13, 2024

Category: General 2024 annual general meeting of the EFFAB (European Forum of Farm Animal Breeders)

June 12, 2024 June 13, 2024

Category: General WG02 MEETING

June 13, 2024

June 14, 2024
June 15, 2024
June 16, 2024
June 17, 2024
June 18, 2024
June 19, 2024
June 20, 2024
June 21, 2024
June 22, 2024
June 23, 2024
June 24, 2024
June 25, 2024

Category: General GeneHumdi #SummerSchool2024

June 26, 2024 June 28, 2024

The course will be locally organized by esteemed Dr. Duško Lainšček and Prof Roman Jerala from the National Chemistry Institut (Ljubljana, Slovenia). They will count with the collaboration of Dr. Dhano Gupta from Institute of Developmental & Regenerative Medicine, Oxford university (Oxford, UK).

The course orchestrates around dissecting efficacy and specificity of cutting-edge genome editing technologies considering the major layers that are needed for the success of clinical genome editing interventions. The syllabus articulates around 3 blocks:
1) NVDM: Non-Viral Delivery Methods.
In which we will learn about efficacy and specificity of genome editing delivery tools. And also, applications across different cell types and approaches in clinical settings.
2) Comparative Analyses of Genome Editing (GE)tools.
Evaluating efficacy and specificity of various genome editing tools. And including the comparison of different delivery methods for optimal outcomes.
3) In Vivo Genome Editing Techniques.
Investigating in vivo genome editing techniques in animal models and clinical scenarios. And assessing efficacy and specificity within specific tissues and organs.

From the Genome Editing for the treatment of human diseases (GeneHumdi, COST CA21113), we are happy to announce that we count with the support and expertise of many members interested and the participation of the action chair Karim Benabdel Lah and SCC F. Javier Molina as coordinators.

Category: General GeneHumdi #SummerSchool2024

June 26, 2024 June 28, 2024

The course will be locally organized by esteemed Dr. Duško Lainšček and Prof Roman Jerala from the National Chemistry Institut (Ljubljana, Slovenia). They will count with the collaboration of Dr. Dhano Gupta from Institute of Developmental & Regenerative Medicine, Oxford university (Oxford, UK).

The course orchestrates around dissecting efficacy and specificity of cutting-edge genome editing technologies considering the major layers that are needed for the success of clinical genome editing interventions. The syllabus articulates around 3 blocks:
1) NVDM: Non-Viral Delivery Methods.
In which we will learn about efficacy and specificity of genome editing delivery tools. And also, applications across different cell types and approaches in clinical settings.
2) Comparative Analyses of Genome Editing (GE)tools.
Evaluating efficacy and specificity of various genome editing tools. And including the comparison of different delivery methods for optimal outcomes.
3) In Vivo Genome Editing Techniques.
Investigating in vivo genome editing techniques in animal models and clinical scenarios. And assessing efficacy and specificity within specific tissues and organs.

From the Genome Editing for the treatment of human diseases (GeneHumdi, COST CA21113), we are happy to announce that we count with the support and expertise of many members interested and the participation of the action chair Karim Benabdel Lah and SCC F. Javier Molina as coordinators.

Category: General GeneHumdi #SummerSchool2024

June 26, 2024 June 28, 2024

The course will be locally organized by esteemed Dr. Duško Lainšček and Prof Roman Jerala from the National Chemistry Institut (Ljubljana, Slovenia). They will count with the collaboration of Dr. Dhano Gupta from Institute of Developmental & Regenerative Medicine, Oxford university (Oxford, UK).

The course orchestrates around dissecting efficacy and specificity of cutting-edge genome editing technologies considering the major layers that are needed for the success of clinical genome editing interventions. The syllabus articulates around 3 blocks:
1) NVDM: Non-Viral Delivery Methods.
In which we will learn about efficacy and specificity of genome editing delivery tools. And also, applications across different cell types and approaches in clinical settings.
2) Comparative Analyses of Genome Editing (GE)tools.
Evaluating efficacy and specificity of various genome editing tools. And including the comparison of different delivery methods for optimal outcomes.
3) In Vivo Genome Editing Techniques.
Investigating in vivo genome editing techniques in animal models and clinical scenarios. And assessing efficacy and specificity within specific tissues and organs.

From the Genome Editing for the treatment of human diseases (GeneHumdi, COST CA21113), we are happy to announce that we count with the support and expertise of many members interested and the participation of the action chair Karim Benabdel Lah and SCC F. Javier Molina as coordinators.

June 29, 2024
June 30, 2024

Last GenEHumDi Blog entry

Webinar series 2024

YOUNG WEBINAR SERIES 🚀 GenE-HumDi News! 🚀 Are you a young researcher looking to expand your knowledge and network? Look ...
Read More

Welcome

A woman in a laboratory

Welcome to the Genome Editing for the treatment of human Disease Network (GeneHumdi | COST action CA21113) Website. We are Academia and industry scientist, translational scientist, clinicians, regulatory agents, and industry partners dedicated to the improvement and translation of Gene Editing protocols to treat diseases lacking sound medical care or susceptible of increase safety and control of the therapeutic interventions through the implementation of precision gene medicine.

About

A person with test tubes

Recent advances on genome editing (GE) technologies have opened the possibility of treating diseases through precise modifications of patients’ genomes. Impressive results have been achieved on animal models of several genetic disorders, infectious diseases as well as cancer and several clinical trials are already on going. However, the inadequate integration of the results of academic research into the research development strategy of pharmaceutical companies, the insufficient interest of academic institution in regulatory science and the absence of established standards to well acceptable risk-benefit ratio by regulatory agencies, preclude its general application for treating human diseases. Therefore, the translation of the GE technologies to address public health needs, require a strong collaboration between basic and clinical research, regulatory bodies and the different stake holders involved for each application. There are several networks to improve or analyse GE technologies for different applications, however, no one cover all the actors involved in gene therapy translation.

The principal aim of the GeneHumdi Action is to bring together pharmaceutical companies, academic institution, science and regulatory agencies, biotechnology firms, patient advocacy association and information technology, in order to tackle knowledge fragmentation with the aim to accelerate the translation of GE technologies to the treatment of human diseases. GeneHumdi is supported by COST (European Cooperation in Science and Technology) which is a funding organisation for research and innovation networks operating in Europe since 1971. In their organigram, GeneHumdi nourishes from the ideas exchange of Management Committee (MC) members from over 24 EU Countries and MC and other members are organized into Working Groups (WG) to distribute GeneHumdi workload and allocate specific question to dedicated experts in each field.

Contact

Action Contacts:

Dr karim BENABDELLAH

Action Chair

0034958 715 500

karim.benabdel@genyo.es

Dr Alessia CAVAZZA

Action Vice Chair

02079052787

a.cavazza@ucl.ac.uk

COST Staff:

Dr Marco

Science Officer

+3225333814

federica.ortelli@cost.eu

Ms Aldona GEMBALIK

Administrative Officer

+32 2 5333825

aldona.gembalik@cost.eu

Leadership:

RoleLeaderPhoneEmail
Action ChairDr karim BENABDELLAH0034958 715 500karim.benabdel@genyo.es
Action Vice ChairDr Alessia CAVAZZA02079052787a.cavazza@ucl.ac.uk
Grant Holder Scientific RepresentativeDr karim BENABDELLAH0034958 715 500karim.benabdel@genyo.es
Science Communication CoordinatorDr Fco. Javier MOLINA ESTEVEZ+34623069770javier.molina@genyo.es
Grant Awarding CoordinatorDr Paula RIO0034913460890paula.rio@ciemat.es
WG2 LeaderDr Rasmus BAK+45 93929100bak@biomed.au.dk
WG3 LeaderDr Yonglun LUO+4587168394alun@biomed.au.dk
WG4 LeaderDr Ayal HENDEL035317316ayal.hendel@biu.ac.il
WG5 LeaderDr Alessia CAVAZZA02079052787a.cavazza@ucl.ac.uk
WG6 LeaderDr Carsten Werner LEDERER22392764Lederer@cing.ac.cy
WG7 LeaderDr Fco. Javier MOLINA ESTEVEZ+ 34 623069770javier.molina@genyo.es

Additional roles:

RoleLeaderPhoneEmail
WG2: Improvement of GE technologies Co-LeaderDr Francisco MARTIN+34 665287238francisco.martin@genyo.es
WG6: Technological transfer and industry Co-LeaderDr Monika PAULE+37060611496monika@caszyme.com
ITC CoordinatorProf Merita XHETANI+355672059369merita.xhetani@fshn.edu.al
WG3: Delivery strategies Co-LeaderDr karim BENABDELLAH0034958 715 500karim.benabdel@genyo.es
WG4: Safety issues: Monitoring and standardization Co-LeaderDr Giandomenico TURCHIANO02039783664g.turchiano@ucl.ac.uk
WG5: Translation into the clinic Co-LeaderDr Paula RIO0034913460890paula.rio@ciemat.es
WG6: Technological transfer and industry Co-LeaderDr philippe DUCHATEAU0181691600philippe.duchateau@cellectis.com
WG6: Regulatory Issues Co-LeaderProf Zoltan IVICS+496103776000zoltan.ivics@pei.de
International AdvisorDr Marcello MARESCA0046(0)706315840Marcello.Maresca@astrazeneca.com
Scroll to top